Articles scientifiques

Managing pregnancy-associated breast cancer: Is more really better?

Auteurs : Peccatori FA, Azim HA Jr
Année : 2016
Journal : Breast
Volume : 30
Pages : 215-216

Liquid biopsy-based clinical research in early breast cancer: The EORTC 90091-10093 Treat CTC trial.

Auteurs : Ignatiadis M, Rack B, Rothé F, Riethdorf S, Decraene C, Bonnefoi H, Dittrich C, Messina C, Beauvois M, Trapp E, Goulioti T, Tryfonidis K, Pantel K, Repollet M, Janni W, Piccart-Gebhart M, Sotiriou C, Litiere S, Pierga JY
Année : 2016
Journal : Eur J Cancer
Volume : 63
Pages : 97-104

Corrigendum: Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells.

Auteurs : Ju YS, Tubio JM, Mifsud W, Fu B, Davies HR, Ramakrishna M, Li Y, Yates L, Gundem G, Tarpey PS, Behjati S, Papaemmanuil E, Martin S, Fullam A, Gerstung M, Nangalia J, Green AR, Caldas C, Borg Å, Tutt A, Lee MT, Vant Veer LJ, Tan BK, Aparicio S, Span PN, Martens JW, Knappskog S, Vincent-Salomon A, Børresen-Dale AL, Eyfjörd JE, Myklebost O, Flanagan AM, Foster C, Neal DE, Cooper C, Eeles R, Bova GS, Lakhani SR, Desmedt C, Thomas G, Richardson AL, Purdie CA, Thompson AM, McDermott U, Yang F, Nik-Zainal S, Campbell PJ, Stratton MR
Année : 2016
Journal : Genome Res
Volume : 26
Pages : 717.2

Frequent incidence of BARD1 truncating mutations in germline DNA from triple negative breast cancer patients.

Auteurs : De Brakeleer S, De Grève J, Desmedt C, Joris S, Sotiriou C, Piccart-Gebhart M, Pauwels I, Teugels E
Année : 2016
Journal : Clin. Genet.
Volume : 89(3)
Pages : 336-40.

Loss of ARID1A activates ANXA1, which serves as a predictive biomarker for trastuzumab resistance.

Auteurs : Berns K, Sonnenblick A, Gennissen A, Brohée S, Hijmans ME, Evers B, Fumagalli D, Desmedt C, Loibl S, Denkert C, Neven P, Guo W, Zhang F, Knijnenburg TA, Bosse T, van der Heijden MS, Hindriksen S, Nijkamp W, Wessels LF, Joensuu H, Mills GB, Beijersbergen RL, Sotiriou C, Bernards R
Année : 2016
Journal : Clin Cancer Res
Volume : 22(21)
Pages : 5238-48

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.

Auteurs : Loibl S, Majewski I, Guarneri V, Nekljudova V, Holmes E, Bria E, Denkert C, Schem C, Sotiriou C, Loi S, Untch M, Conte P, Bernards R, Piccart-Gebhart M, Von Minckwitz G, Baselga J
Année : 2016
Journal : Ann Oncol
Volume : 27(8)
Pages : 1519-25

Consensus on precision medicine for metastatic cancers: a report from the MAP conference.

Auteurs : Swanton C, Soria JC, Bardelli A, Biankin A, Caldas C, Chandarlapaty S, de Koning L, Dive C, Feunteun J, Leung SY, Marais R, Mardis ER, McGranahan N, Middleton G, Quezada SA, Rodón J, Rosenfeld N, Sotiriou C, André F
Année : 2016
Journal : Ann Oncol
Volume : 27(8)
Pages : 1443-8

Challenges in Treating Premenopausal Women with Endocrine-Sensitive Breast Cancer.

Auteurs : Azim HA Jr, Davidson NE, Ruddy KJ
Année : 2016
Journal : Am Soc Clin Oncol Educ Book
Volume : 35
Pages : 23-32

Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial.

Auteurs : Sonnenblick A, de Azambuja E, Agbor-Tarh D, Bradbury I, Campbell C, Huang Y, Dueck AC, Pritchard KI, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Gomez H, Perez EA, Piccart-Gebhart M, Azim HA Jr
Année : 2016
Journal : J Natl Cancer Inst
Volume : 108

Tumour-educated circulating monocytes are powerful candidate biomarkers for diagnosis and disease follow-up of colorectal cancer.

Auteurs : Hamm A, Prenen H, Van Delm W, Di Matteo M, Wenes M, Delamarre E, Schmidt T, Weitz J, Sarmiento R, Dezi A, Gasparini G, Rothé F, Schmitz R, Dhoore A, Iserentant H, Hendlisz A, Mazzone M
Année : 2016
Journal : Gut
Volume : 65(6)
Pages : 990-1000

RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy.

Auteurs : Azim HA, Peccatori FA, Brohée S, Branstetter D, Loi S, Viale G, Piccart-Gebhart M, Dougall WC, Pruneri G, Sotiriou C
Année : 2015
Journal : Breast Cancer Res
Volume : 17
Pages : 24

PIK3CA Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2-Targeted Therapies in Breast Cancer.

Auteurs : Majewski IJ, Nuciforo P, Mittempergher L, Bosma AJ, Eidtmann H, Holmes E, Sotiriou C, Fumagalli D, Jimenez J, Aura C, Prudkin L, Díaz-Delgado MC, de la Peña L, Loi S, Ellis C, Schultz N, de Azambuja E, Harbeck N, Piccart-Gebhart M, Bernards R, Baselga J
Année : 2015
Journal : J. Clin. Oncol.
Volume : 33(12)
Pages : 1334-9

Optimising translational oncology in clinical practice: Strategies to accelerate progress in drug development.

Auteurs : Stahel R, Bogaerts J, Ciardiello F, De Ruysscher D, Dubsky P, Ducreux M, Finn S, Laurent-Puig P, Peters S, Piccart-Gebhart M, Smit E, Sotiriou C, Tejpar S, van Cutsem E, Tabernero J
Année : 2015
Journal : Cancer Treat Rev
Volume : 41(2)
Pages : 129-135

Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive and Triple-Negative Primary Breast Cancers.

Auteurs : Denkert C, Von Minckwitz G, Brase JC, Sinn BV, Gade S, Kronenwett R, Pfitzner BM, Salat C, Loi S, Schmitt WD, Schem C, Fisch K, Darb-Esfahani S, Mehta K, Sotiriou C, Wienert S, Klare P, André F, Klauschen F, Blohmer J, Krappmann K, Schmidt M, Tesch H, Kümmel S, Sinn P, Jackisch C, Dietel M, Reimer T, Untch M, Loibl S
Année : 2015
Journal : J. Clin. Oncol.
Volume : 33(9)
Pages : 983-91

Harmonization of the evaluation of tumor infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs-working group 2014.

Auteurs : Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehne FL, Penault-Llorca F, Perez EA, Thompson EA, Symmans WF, Richardson AL, Brock J, Criscitiello C, Bailey H, Ignatiadis M, Floris G, Sparano J, Kos Z, Nielsen T, Rimm DL, Allison KH, Reis-Filho JS, Loibl S, Sotiriou C, Viale G, Badve S, Adams S, Willard-Gallo K, Loi S
Année : 2015
Journal : Ann Oncol
Volume : 26(2)
Pages : 259-71

CCR 20th Anniversary Commentary: Gene-Expression Signature in Breast Cancer-Where Did It Start and Where Are We Now?

Auteurs : Gingras I, Desmedt C, Ignatiadis M, Sotiriou C
Année : 2015
Journal : Clin Cancer Res
Volume : 21
Pages : 4743-6

Genomic aberrations in young and elderly  breast cancer patients.

Auteurs : Azim HA, Nguyen B, Brohée S, Zoppoli G, Sotiriou C
Année : 2015
Journal : BMC Med
Volume : 13
Pages : 266

Evolving paradigms in multifocal breast cancer.

Auteurs : Salgado R, Aftimos P, Sotiriou C, Desmedt C
Année : 2015
Journal : Semin. Cancer Biol.
Volume : 31C
Pages : 111-118

Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial.

Auteurs : Sonnenblick A, Brohée S, Fumagalli D, Rothé F, Vincent D, Ignatiadis M, Desmedt C, Salgado R, Sirtaine N, Loi S, Neven P, Loibl S, Denkert C, Joensuu H, Piccart-Gebhart M, Sotiriou C
Année : 2015
Journal : Oncotarget
Volume : 6
Pages : 30306-16

Principles Governing A-to-I RNA Editing in the Breast Cancer Transcriptome.

Auteurs : Fumagalli D, Gacquer D, Rothé F, Lefort A, Libert F, Brown D, Kheddoumi N, Shlien A, Konopka T, Salgado R, Larsimont D, Polyak K, Willard-Gallo K, Desmedt C, Piccart-Gebhart M, Abramowicz M, Campbell PJ, Sotiriou C, Detours V
Année : 2015
Journal : Cell Rep
Volume : 13
Pages : 277-89